Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 2, 2023 and accepted by EDGAR at May 2, 2023, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $2.37bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $266.9m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $241.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $779.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $191.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $699.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $2.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $2.72 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 260,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $899.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $42.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $132.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $9.29bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $12.97bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $18.97bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $3.03bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $4.54bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $14.43bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-23-000012. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.